Form 4: OPKO Health CEO Phillip Frost Granted 500,000 Stock Options

OPKO Health's CEO and Chairman, Phillip Frost, was granted 500,000 stock options with an exercise price of $1.31, vesting over four years.

Summary

• Phillip Frost, M.D., who serves as Director, 10% Owner, and CEO & Chairman of OPKO Health, Inc. (OPK), reported an acquisition of derivative securities.
• The transaction involved the grant of 500,000 stock options (Right to Buy) on May 27, 2025.
• Each option has an exercise price of $1.31.
• The options will vest in four equal annual installments, commencing on May 27, 2026.
• The expiration date for these stock options is May 26, 2035.
• Following this reported transaction, Phillip Frost beneficially owns 500,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 is a routine disclosure, the grant of stock options to the CEO and Chairman is a positive signal for corporate governance as it aligns executive incentives with shareholder value creation over the long term. It does not, however, provide direct financial performance data.

Positives

• The grant of stock options to the CEO and Chairman, Phillip Frost, aligns management's long-term interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• The vesting schedule over four years encourages sustained performance and commitment from the executive.

Future Outlook

The vesting schedule of the stock options, which extends over four years starting May 27, 2026, indicates a long-term incentive structure for the CEO, aligning his future compensation with the company's performance over this period.

Industry Context

The grant of stock options to key executives like the CEO is a common practice in the biotechnology and pharmaceutical industries, serving as a performance incentive and a component of executive compensation packages. This aligns the executive's financial interests with the long-term growth and shareholder value creation of the company.

Comparison to Industry Standards

• Executive stock option grants are a standard component of compensation across publicly traded companies, particularly in growth-oriented sectors like biotech.
• The four-year vesting schedule is typical for long-term incentive plans, comparable to practices at companies such as Pfizer Inc. or Amgen Inc., which often use multi-year vesting to retain talent and incentivize sustained performance.
• The exercise price being set at the market price on the grant date (implied by $0 derivative price and $1.31 exercise price) is a common practice for incentive stock options, ensuring the executive benefits only if the stock price appreciates.

Stakeholder Impact

• Shareholders: The grant of stock options to the CEO and Chairman can be viewed positively as it aligns management's financial incentives with the company's stock performance, potentially leading to increased shareholder value.
• Management/Executives: Phillip Frost benefits from a long-term incentive that rewards him for future stock price appreciation.

Next Steps

• The stock options will begin to vest in four equal annual installments starting May 27, 2026.
• Phillip Frost will have the right to exercise these options at $1.31 per share until their expiration on May 26, 2035.

Key Dates

Keywords

OPKO Health, OPK, Phillip Frost, Stock Options, Executive Compensation, SEC Form 4, Insider Transaction, Equity Grant